This is a routine governance filing with no immediate financial implications. The recent board appointment suggests continuity in leadership. Monitor for any shareholder proposals or voting outcomes that could signal governance changes.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 8 $5.27entry
- T+1 · 7mo ago −0.38%α −0.95% · $5.25
- T+5 · 7mo ago +5.12%α +1.61% · $5.54
- T+20 · 7mo ago +26.38%α +17.83% · $6.66
- T+60 · 4mo ago +74.57%α +64.12% · $9.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teladoc Health is holding its 2026 annual meeting to elect nine directors, approve executive compensation, and ratify its auditor. This follows the recent appointment of Susan R. Salka to the board, indicating board continuity and governance stability.
Key Financial Metrics
Key Facts
- Annual meeting to elect nine directors, approve executive compensation, and ratify auditor Ernst & Young LLP
- Recent 8-K filing confirms appointment of Susan R. Salka to the board
- Board composition remains stable with nine members
- Meeting agenda is standard for annual governance
Financial Impact
No immediate financial impact
Risk Factors
- Potential for shareholder activism if voting results are contentious
- Board composition could be challenged if any director elections are close
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001477449-26-000021 |
| Document: 0001477449-26-000021-index-headers.html | 0001477449-26-000021 |
| Document: 0001477449-26-000021-index.html | 0001477449-26-000021 |
| Document: 0001477449-26-000021.txt | 0001477449-26-000021 |
Track record
24 reports on TDOC
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +2.52% at T+1 after the Oct 28, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.60 Now $8.70 +1.22% settles Nov 17
- Nov 6, 202610d ago 144 Neutral 3/10 Entry $8.77 to $8.98 Now $8.70 −0.80% ▲ +2.39% +0.03% vs SPY
- Nov 3, 202613d ago 3 / PRESS-RELEASE Neutral 2/10 Entry $9.70 to $9.41 Now $8.70 −10.31% ▼ −2.99% +1.42% vs SPY
- Nov 3, 202614d ago PTAB Trial Neutral 3/10 Entry $8.89 to $9.70 Now $8.70 −2.14% ▲ +9.11% +7.46% vs SPY
- Oct 28, 202619d ago Press Release Bearish 6/10 No price data
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $8.73 to $8.51 Now $8.70 +0.34% ▲ +2.52% +0.75% vs SPY
- Oct 28, 202620d ago PTAB Trial Neutral 3/10 Entry $8.73 to $8.51 Now $8.70 −0.34% ▼ −2.52% −0.75% vs SPY
- Oct 8, 20265w ago SC 13G Neutral 3/10 Entry $5.54 to $5.77 Now $8.70 +57.04% ▲ +4.15% +3.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.09 to $5.89 Now $8.70 +42.86% ▼ −3.28% −2.54% vs SPY
- Sep 11, 20269w ago 144 Neutral 2/10 Entry $6.16 to $6.50 Now $8.70 +41.23% ▲ +5.52% +5.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers